These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 22914441

  • 1. Development of an ELISA based bridging assay as a surrogate measure of ADCC.
    Miller AS, Tejada ML, Gazzano-Santoro H.
    J Immunol Methods; 2012 Nov 30; 385(1-2):45-50. PubMed ID: 22914441
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 3. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 4. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
    Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M.
    Mol Immunol; 2011 Jul 28; 48(12-13):1512-7. PubMed ID: 21570725
    [Abstract] [Full Text] [Related]

  • 5. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K.
    Clin Cancer Res; 2005 Mar 15; 11(6):2327-36. PubMed ID: 15788684
    [Abstract] [Full Text] [Related]

  • 6. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL, Smith CS, Clark MR.
    J Immunol Methods; 2010 Mar 31; 354(1-2):20-33. PubMed ID: 20138184
    [Abstract] [Full Text] [Related]

  • 7. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 8. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T.
    J Immunol Methods; 2014 Dec 01; 414():69-81. PubMed ID: 25086226
    [Abstract] [Full Text] [Related]

  • 9. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 10. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.
    J Immunol Methods; 2011 Feb 28; 365(1-2):132-41. PubMed ID: 21185301
    [Abstract] [Full Text] [Related]

  • 11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 28; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 12. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, Shitara K, Satoh M.
    BMC Cancer; 2009 Feb 18; 9():58. PubMed ID: 19226457
    [Abstract] [Full Text] [Related]

  • 13. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
    Chung S, Lin YL, Reed C, Ng C, Cheng ZJ, Malavasi F, Yang J, Quarmby V, Song A.
    J Immunol Methods; 2014 May 18; 407():63-75. PubMed ID: 24704820
    [Abstract] [Full Text] [Related]

  • 14. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT, Aggarwal P, Cirelli D, Gu L, Surowy T, Mozier NM.
    J Immunol Methods; 2017 Feb 18; 441():56-66. PubMed ID: 27939300
    [Abstract] [Full Text] [Related]

  • 15. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L.
    Exp Hematol; 2006 Jun 18; 34(6):753-9. PubMed ID: 16728280
    [Abstract] [Full Text] [Related]

  • 16. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML.
    Mol Immunol; 2016 May 18; 73():69-75. PubMed ID: 27058641
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X.
    Hum Antibodies; 2010 May 18; 19(4):89-99. PubMed ID: 21178280
    [Abstract] [Full Text] [Related]

  • 19. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
    Sung AP, Tang JJ, Guglielmo MJ, Redelman D, Smith-Gagen J, Bateman L, Hudig D.
    J Immunol Methods; 2018 Jan 18; 452():63-72. PubMed ID: 29113954
    [Abstract] [Full Text] [Related]

  • 20. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.
    Cancer Res; 2004 Jul 01; 64(13):4664-9. PubMed ID: 15231679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.